USPTO Examiner WOITACH JOSEPH T - Art Unit 1687

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19073665METHODS FOR USING MOSAICISM IN NUCLEIC ACIDS SAMPLED DISTAL TO THEIR ORIGINMarch 2025August 2025Allow610YesNo
18932298SYSTEMS AND METHODS FOR DETERMINING NUCLEIC ACIDSOctober 2024August 2025Allow1020NoNo
18932442SYSTEMS AND METHODS FOR DETERMINING NUCLEIC ACIDSOctober 2024September 2025Allow1120NoNo
18932378SYSTEMS AND METHODS FOR DETERMINING NUCLEIC ACIDSOctober 2024September 2025Allow1120NoNo
18613618METHODS FOR USING MOSAICISM IN NUCLEIC ACIDS SAMPLED DISTAL TO THEIR ORIGINMarch 2024December 2024Allow911YesNo
18198763SEQUENCING METHODSMay 2023November 2024Allow1821YesNo
18174019METHOD FOR ASSESSING DRUG-RESISTANT STENOTROPHOMONAS MALTOPHILIA AND DRUG-RESISTANT STENOTROPHOMONAS MALTOPHILIA ASSESSING SYSTEMFebruary 2023May 2025Abandon2711NoNo
18167803Methods and Systems for Analyzing Nucleic Acid MoleculesFebruary 2023November 2024Abandon2121NoNo
18056656Methods and Systems for Analyzing Nucleic Acid MoleculesNovember 2022November 2024Abandon2430YesNo
17901826DIAGNOSTIC TOOL FOR SCREENING THE IMPACT OF PRODUCT INGREDIENTS FOR UROGENITAL MICROBIOMES THERAPIESSeptember 2022March 2025Abandon3041NoNo
17784576GENERATING PROTEIN SEQUENCES USING MACHINE LEARNING TECHNIQUES BASED ON TEMPLATE PROTEIN SEQUENCESJune 2022September 2025Abandon3941YesNo
17689298BLADDER OR BOWEL DYSFUNCTION ASSESSMENT SYSTEMS AND METHODSMarch 2022March 2026Abandon4810NoNo
17597904ANALYSIS METHOD FOR DETERMINING HAPLOTYPES OF FILIAL GENERATION OBJECTS AND DEVICEJanuary 2022March 2026Abandon5001NoNo
17618502A Construction Method for Automatic Sleep Staging and Use ThereofDecember 2021February 2026Abandon5001NoNo
17643105BRAIN-BASED SYSTEM AND METHODS FOR EVALUATING TREATMENT EFFICACY TESTING WITH OBJECTIVE SIGNAL DETECTION AND EVALUATION FOR INDIVIDUAL, GROUP OR NORMATIVE ANALYSISDecember 2021January 2026Abandon5010NoNo
17494632Early Detection of Cancer, Recurrence Monitoring and Companion Diagnostics via Liquid BiopsyOctober 2021June 2025Abandon4401NoNo
17394591SYSTEMS AND METHODS FOR MODELLING PHYSIOLOGIC FUNCTION USING A COMBINATION OF MODELS OF VARYING DETAILAugust 2021September 2025Allow5010YesNo
17374000SYSTEMS AND METHODS FOR DETERMINING NUCLEIC ACIDSJuly 2021November 2024Allow4021YesNo
17159725TRANSCRIPTION FACTOR PROFILINGJanuary 2021March 2026Allow6071YesNo
17129054METHOD FOR DISCOVERING PHARMACOGENOMIC BIOMARKERSDecember 2020January 2026Abandon6010NoNo
17109723METHODS AND PROCESSES FOR NON-INVASIVE ASSESSMENT OF GENETIC VARIATIONSDecember 2020February 2026Allow6011YesNo
17049667MOLECULAR TYPING OF MULTIPLE MYELOMA AND APPLICATIONOctober 2020October 2024Allow4811NoNo
17075690Methods for Introducing Mutations That Alter the Probability of Intranucleic Acid Base Pairing of a Conserved Structured Nucleotide and Related CompositionsOctober 2020September 2025Abandon5901NoNo
17070668GENE EXPRESSION SIGNATURE OF HYPERPROGRESSIVE DISEASE (HPD) IN PATIENTS AFTER ANTI-PD-1 IMMUNOTHERAPYOctober 2020March 2025Allow5321YesNo
17017441GENETIC ANALYSIS METHODSeptember 2020June 2025Abandon5701NoNo
16985980METHODS OF QUALITY CONTROL USING SINGLE-NUCLEOTIDE POLYMORPHISMS IN PRE-IMPLANTATION GENETIC SCREENINGAugust 2020March 2026Allow6021YesNo
16963385METHOD AND SYSTEM FOR SIGNAL PROCESSING REHABILITATION EXERCISE SIGNALSJuly 2020August 2025Allow6011YesNo
16889917PULSE CALLER AND BASE CALLERJune 2020January 2025Allow5611YesNo
15929970METHODS, SYSTEMS, AND COMPUTER-READABLE MEDIA FOR ACCELERATED BASE CALLINGJune 2020October 2024Allow5311NoNo
16874215METHYLATION PATTERN ANALYSIS OF HAPLOTYPES IN TISSUES IN A DNA MIXTUREMay 2020May 2025Allow6021YesNo
16837210DETECTING GENETIC COPY NUMBER VARIATIONApril 2020August 2024Allow5220NoNo
16819190SYSTEM, METHOD AND SOFTWARE FOR CALCULATION OF CANNABIS DRUG EFFICIENCY INDEX (CDEI)March 2020December 2022Abandon3311NoNo
16793405SYSTEM AND METHOD FOR MANAGING GENOMIC TESTING RESULTSFebruary 2020January 2025Abandon5911NoNo
16627193SYSTEMS AND METHODS FOR MHC CLASS II EPITOPE PREDICTIONDecember 2019March 2025Allow6021YesNo
16669270METHODS AND COMPOSITIONS FOR GERMLINE VARIANT DETECTIONOctober 2019July 2025Allow6041YesNo
16597707METHODS AND PROCESSES FOR NON-INVASIVE ASSESSMENT OF GENETIC VARIATIONSOctober 2019August 2024Allow5820YesNo
16590303METHODS AND SYSTEMS FOR VISUALIZING AND EVALUATING DATAOctober 2019August 2024Allow5820NoNo
16579508COMPUTER-IMPLEMENTED SYSTEM AND METHOD FOR IDENTIFYING SIMILAR PATIENTSSeptember 2019March 2025Allow6021YesYes
16562312METHODS FOR GENOME ASSEMBLY, HAPLOTYPE PHASING, AND TARGET INDEPENDENT NUCLEIC ACID DETECTIONSeptember 2019August 2025Abandon6040YesNo
16554286CELL-FREE NUCLEIC ACIDS FOR THE ANALYSIS OF THE HUMAN MICROBIOME AND COMPONENTS THEREOFAugust 2019September 2024Allow6031YesNo
16450775GENOME EXPLORER SYSTEM TO PROCESS AND PRESENT NUCLEOTIDE VARIATIONS IN GENOME SEQUENCE DATAJune 2019September 2024Allow6021YesNo
16433380METHODS, SYSTEMS, COMPUTER READABLE MEDIA, AND KITS FOR SAMPLE IDENTIFICATIONJune 2019July 2024Allow6021YesNo
16428656SEQUENCING METHODSMay 2019June 2024Allow6021YesNo
16411849METHOD AND SYSTEM FOR IDENTIFICATION OF KEY DRIVER ORGANISMS FROM MICROBIOME / METAGENOMICS STUDIESMay 2019September 2024Allow6021YesNo
16285604METHODS FOR TREATING BARRETT'S METAPLASIA AND ESOPHAGEAL ADENOCARCINOMAFebruary 2019September 2023Allow5520NoNo
16245343METHODS FOR FLOW SPACE QUALITY SCORE PREDICTION BY NEURAL NETWORKSJanuary 2019February 2025Abandon6040NoNo
16241288PROCESS FOR ALIGNING TARGETED NUCLEIC ACID SEQUENCING DATAJanuary 2019August 2025Abandon6061YesNo
16065982SYSTEM AND METHOD FOR ANALYZING GENOTYPE USING GENETIC VARIATION INFORMATION ON INDIVIDUAL'S GENOMENovember 2018March 2026Abandon60100YesNo
16093588DETECTING CANCER DRIVER GENES AND PATHWAYSOctober 2018March 2025Allow6031YesNo
16119961IDENTIFYING FALSE POSITIVE VARIANTS USING A SIGNIFICANCE MODELAugust 2018August 2025Allow6041YesNo
16033983GRANULAR ELECTION OF PREDICTIVE POLYGENIC MODELSJuly 2018February 2020Abandon1961YesYes
15771288METHOD AND SYSTEM FOR SELECTING CUSTOMIZED DRUG USING GENOMIC NUCLEOTIDE SEQUENCE VARIATION INFORMATION AND SURVIVAL INFORMATION OF CANCER PATIENTMay 2018October 2024Abandon6041NoNo
15768939Multiallelic Genotyping of Single Nucleotide Polymorphisms and IndelsApril 2018September 2025Abandon6051NoNo
15766733METHODS AND APPLICATIONS OF GENE FUSION DETECTION IN CELL-FREE DNA ANALYSISApril 2018December 2025Allow6041YesYes
15947463System for Diagnosing of Avellino Corneal DystrophyApril 2018April 2022Allow4851YesNo
15763577Typing and Assembling Discontinuous Genomic ElementsMarch 2018August 2025Abandon6051YesNo
15838724Applied Computer Technology for Management, Synthesis, Visualization, and Exploration of Parameters in Large Multi-Parameter Data SetsDecember 2017January 2025Allow6051YesNo
15660858Nervous System Modeling ToolJuly 2017November 2023Abandon6041YesNo
15408402METHODS FOR MAKING GENETIC REGULATORY ELEMENTSJanuary 2017August 2024Allow6071YesNo
15331792NOVEL CRISPR ENZYMES AND SYSTEMSOctober 2016April 2024Allow6071NoNo
14775252METHODS AND SYSTEMS FOR ALIGNING REPETITIVE DNA ELEMENTSSeptember 2015June 2025Abandon6081YesYes
14743713STRING GRAPH ASSEMBLY FOR POLYPLOID GENOMESJune 2015September 2024Allow6081NoNo
14651349METHOD TO CALCULATE FREE ENERGIESJune 2015March 2020Abandon5781YesYes
14470628Identifying Possible Disease-Causing Genetic Variants by Machine Learning ClassificationAugust 2014November 2025Abandon6071NoYes
14355408Method And System For Detection Of An OrganismApril 2014July 2016Abandon2791YesYes
14229321Method and System for Matching Probabilistic Identitypes on a DatabaseMarch 2014May 2021Abandon60101NoYes
13912318Systems and Methods for Automatically Displaying Patterns in Biological Monitoring DataJune 2013February 2024Allow6060YesYes

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner WOITACH, JOSEPH T.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
4
Examiner Affirmed
3
(75.0%)
Examiner Reversed
1
(25.0%)
Reversal Percentile
37.9%
Lower than average

What This Means

With a 25.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
16
Allowed After Appeal Filing
1
(6.2%)
Not Allowed After Appeal Filing
15
(93.8%)
Filing Benefit Percentile
12.0%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 6.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner WOITACH, JOSEPH T - Prosecution Strategy Guide

Executive Summary

Examiner WOITACH, JOSEPH T works in Art Unit 1687 and has examined 54 patent applications in our dataset. With an allowance rate of 59.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 10000 months.

Allowance Patterns

Examiner WOITACH, JOSEPH T's allowance rate of 59.3% places them in the 19% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by WOITACH, JOSEPH T receive 3.54 office actions before reaching final disposition. This places the examiner in the 94% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by WOITACH, JOSEPH T is 10000 months. This places the examiner in the 0% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +38.5% benefit to allowance rate for applications examined by WOITACH, JOSEPH T. This interview benefit is in the 86% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 14.4% of applications are subsequently allowed. This success rate is in the 10% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 23.5% of cases where such amendments are filed. This entry rate is in the 31% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 2% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 50.0% of appeals filed. This is in the 14% percentile among all examiners. Of these withdrawals, 75.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.

Petition Practice

When applicants file petitions regarding this examiner's actions, 95.5% are granted (fully or in part). This grant rate is in the 89% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 3% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 6.2% of allowed cases (in the 83% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.